TH Theratechnologies Inc.

Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASH

Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASH
EN
13/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE

Theratechnologies Announces Completion of Acquisition by Future Pak

Theratechnologies Announces Completion of Acquisition by Future Pak MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the...

 PRESS RELEASE

Theratechnologies annonce la réalisation de l’acquisition par Future P...

Theratechnologies annonce la réalisation de l’acquisition par Future Pak MONTRÉAL, 25 sept. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’hui la réalisation du plan d’arrangement pris en vertu du chapitre XVI – section II de la Loi sur les sociétés par actions (Québec) annoncé précédemment et auquel est partie CB Biotechnology, LLC (l’« Acquéreur »), un membre du même groupe que Future Pak, LLC (« Future Pak »), aux termes duquel l’Acqué...

 PRESS RELEASE

Theratechnologies reçoit l’approbation définitive du tribunal relative...

Theratechnologies reçoit l’approbation définitive du tribunal relativement au plan d’arrangement proposé visant son acquisition par Future Pak MONTRÉAL, 16 sept. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’hui que la Société a obtenu l’ordonnance définitive de la Cour supérieure du Québec (chambre commerciale) approuvant le plan d’arrangement (l’« Arrangement ») pris en vertu du chapitre XVI – section II de la Loi sur les sociétés par ...

 PRESS RELEASE

Theratechnologies Receives Final Court Approval of Proposed Plan of Ar...

Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Pu...

 PRESS RELEASE

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to...

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”). At the special meetin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch